Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENVISION
2017-002432-17Phase 3Unknown
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Sep 2017
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute porphyria, porphyria and acute intermittent porphyria (AIP) comparing Givlaari arm with Placebo arm (2 arms). Primary endpoint: Annualized porphyria attack rate over 6 months. Status: unknown.
02
Drugs
givosiran
03
Conditions
acute porphyriaporphyriaacute intermittent porphyria (AIP)
Beyond the preview
Go deeper on 2017-002432-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002432-17.